About this trial
AIMS 2 \& 3:
In this study the investigators seek to formally compare reproducibility and accuracy of KS lesion size measurements between SkinScan3D and the current standard of care manual measurement method. The investigators will then test the SS3D device on 100 patients in a variety of real-world practice locations to determine whether the device will be usable, acceptable, appropriate, and feasible in routine care settings.
Eligibility criteria
Qualifiers
Adults age ≥18 years old
Histopathology-confirmed Kaposi Sarcoma
At least 3 skin lesions
Capable of informed consent
Disqualifiers
Patients not initiating Kaposi Sarcoma treatment
Very ill patients requiring hospitalization
Adults age ≥18 years old
Histopathology-confirmed Kaposi Sarcoma
Trial design
Treatments tested in this trial
- SkinScan3D
Treatment groups
Sponsors and collaborators
Washington University School of Medicine
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Pensievision
Collaborator
Kenya Medical Research Institute
Collaborator
Makerere University
Collaborator